{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,5,14]],"date-time":"2026-05-14T07:17:49Z","timestamp":1778743069191,"version":"3.51.4"},"reference-count":20,"publisher":"Springer Science and Business Media LLC","issue":"4","license":[{"start":{"date-parts":[[2020,1,10]],"date-time":"2020-01-10T00:00:00Z","timestamp":1578614400000},"content-version":"tdm","delay-in-days":0,"URL":"http:\/\/www.springer.com\/tdm"},{"start":{"date-parts":[[2020,1,10]],"date-time":"2020-01-10T00:00:00Z","timestamp":1578614400000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/www.springer.com\/tdm"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Cardiovasc Toxicol"],"published-print":{"date-parts":[[2020,8]]},"DOI":"10.1007\/s12012-020-09562-w","type":"journal-article","created":{"date-parts":[[2020,1,10]],"date-time":"2020-01-10T13:02:44Z","timestamp":1578661364000},"page":"437-442","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":20,"title":["Various Manifestations of 5-Fluorouracil Cardiotoxicity: A Multicenter Case Series and Review of Literature"],"prefix":"10.1007","volume":"20","author":[{"ORCID":"https:\/\/orcid.org\/0000-0001-6742-9061","authenticated-orcid":false,"given":"John D.","family":"Allison","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Toug","family":"Tanavin","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Yang","family":"Yang","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Gilad","family":"Birnbaum","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Umair","family":"Khalid","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"297","published-online":{"date-parts":[[2020,1,10]]},"reference":[{"key":"9562_CR1","unstructured":"Arney, K. (2016). \u201cFluorouracil\u201d. Chemistry World. Audio blog post. Royal Society of Chemistry. https:\/\/www.chemistryworld.com\/podcasts\/fluorouracil\/1017474.article."},{"issue":"21","key":"9562_CR2","doi-asserted-by":"publisher","first-page":"8643","DOI":"10.1158\/0008-5472.CAN-07-6611","volume":"68","author":"VT Devita Jr","year":"2008","unstructured":"Devita, V. T., Jr., & Chu, E. (2008). A history of cancer chemotherapy. Cancer Research,68(21), 8643\u20138653.","journal-title":"Cancer Research"},{"key":"9562_CR3","doi-asserted-by":"publisher","first-page":"663","DOI":"10.1038\/179663a0","volume":"179","author":"C Heidelberger","year":"1957","unstructured":"Heidelberger, C., Chaudhuari, N. K., & Danenberg, P. (1957). Fluorinated pyrimidines. A new class of tumor inhibitory compounds. Nature,179, 663\u2013666.","journal-title":"Nature"},{"issue":"4","key":"9562_CR4","doi-asserted-by":"publisher","first-page":"299","DOI":"10.1023\/A:1006416410198","volume":"18","author":"JL Grem","year":"2000","unstructured":"Grem, J. L. (2000). 5-Fluorouracil: Forty-plus and still ticking. A review of its preclinical and clinical development. Investigational New Drugs,18(4), 299\u2013313.","journal-title":"Investigational New Drugs"},{"issue":"16","key":"9562_CR5","doi-asserted-by":"publisher","first-page":"2938","DOI":"10.1200\/JCO.2000.18.16.2938","volume":"18","author":"A de Gramont","year":"2000","unstructured":"de Gramont, A., Figer, A., Seymour, M., et al. (2000). Leucovorin and fluorouracil with or without oxaliplatin as first-line treatment in advanced colorectal cancer. Journal of Clinical Oncology,18(16), 2938.","journal-title":"Journal of Clinical Oncology"},{"issue":"3","key":"9562_CR6","doi-asserted-by":"publisher","first-page":"374","DOI":"10.1177\/106002809402800314","volume":"28","author":"AJ Anand","year":"1994","unstructured":"Anand, A. J. (1994). Fluorouracil cardiotoxicity. Annals of Pharmacotherapy,28(3), 374.","journal-title":"Annals of Pharmacotherapy"},{"issue":"6","key":"9562_CR7","doi-asserted-by":"publisher","first-page":"441","DOI":"10.1159\/000227226","volume":"50","author":"SS Akhtar","year":"1993","unstructured":"Akhtar, S. S., Salim, K. P., & Bano, Z. A. (1993). Symptomatic cardiotoxicity with high dose 5-fluorouracil infusion: A prospective study. Oncology,50(6), 441.","journal-title":"Oncology"},{"issue":"7","key":"9562_CR8","doi-asserted-by":"publisher","first-page":"863","DOI":"10.1016\/j.cjca.2016.01.027","volume":"32","author":"R Mougdil","year":"2016","unstructured":"Mougdil, R., & Yeh, E. T. (2016). Mechanisms of cardiotoxicity of cancer chemotherapeutic agents: Cardiomyopathy and beyond. Canadian Journal of Cardiology,32(7), 863\u2013870.","journal-title":"Canadian Journal of Cardiology"},{"issue":"5","key":"9562_CR9","doi-asserted-by":"publisher","first-page":"453","DOI":"10.5603\/CJ.2012.0084","volume":"19","author":"MF Sorrentino","year":"2012","unstructured":"Sorrentino, M. F., Kim, J., Foderaro, A. E., & Truesdell, A. G. (2012). 5-Fluorouracil induced cardiotoxicity: Review of the literature. Cardiology Journal,19(5), 453\u2013458.","journal-title":"Cardiology Journal"},{"key":"9562_CR10","doi-asserted-by":"crossref","unstructured":"Sara, J. D., Kaur, J., Khodadadi, R., Rehman, M., Lobo, R., Chakrabarti, S., Hermann, J., Lerman, A., Grothey, A. (2018). 5-Fluorouracil and cardiotoxicity: A review. Therapeutic Advances in Medical Oncology, 10, 1\u201318.","DOI":"10.1177\/1758835918780140"},{"key":"9562_CR11","doi-asserted-by":"publisher","first-page":"47","DOI":"10.1186\/2050-6511-15-47","volume":"15","author":"A Polk","year":"2014","unstructured":"Polk, A., Visitsen, K., Vaage-Nilsen, M., & Nielson, D. (2014). A systematic review of the pathophysiology of 5-fluorouracil-induced cardiotoxicity. BMC Pharmacology and Toxicology,15, 47\u201358.","journal-title":"BMC Pharmacology and Toxicology"},{"issue":"7","key":"9562_CR12","doi-asserted-by":"publisher","first-page":"2242","DOI":"10.1002\/1097-0142(19931001)72:7<2242::AID-CNCR2820720730>3.0.CO;2-E","volume":"72","author":"C Schober","year":"1993","unstructured":"Schober, C., Papageorgiou, E., Harstrick, A., et al. (1993). Cardiotoxicity of 5-fluorouracil in combination with folinic acid in patients with gastrointestinal cancer. Cancer,72(7), 2242\u20132247.","journal-title":"Cancer"},{"issue":"1","key":"9562_CR13","doi-asserted-by":"publisher","first-page":"75","DOI":"10.1007\/s00432-007-0250-9","volume":"134","author":"C Kosmas","year":"2008","unstructured":"Kosmas, C., Kallistratos, M. S., Kopertides, P., et al. (2008). Cardiotoxicity of fluoropyrimidines in different schedules of administration: A prospective study. Journal of Cancer Research and Clinical Oncology,134(1), 75\u201382.","journal-title":"Journal of Cancer Research and Clinical Oncology"},{"issue":"4","key":"9562_CR14","doi-asserted-by":"crossref","first-page":"729","DOI":"10.1002\/j.1875-9114.1997.tb03748.x","volume":"17","author":"CC Meyer","year":"1997","unstructured":"Meyer, C. C., Calis, K. A., Burke, L. B., et al. (1997). Symptomatic cardiotoxicity associated with 5-fluorouracil. Pharmacotherapy,17(4), 729\u2013736.","journal-title":"Pharmacotherapy"},{"issue":"4","key":"9562_CR15","doi-asserted-by":"publisher","first-page":"487","DOI":"10.1007\/s00280-005-0178-1","volume":"58","author":"SA Jensen","year":"2006","unstructured":"Jensen, S. A., & Sorensen, J. B. (2006). Risk factors and prevention of cardiotoxicity induced by 5-fluorouracil or capecitabine. Cancer Chemotherapy and Pharmacology,58(4), 487\u2013493.","journal-title":"Cancer Chemotherapy and Pharmacology"},{"issue":"2","key":"9562_CR16","doi-asserted-by":"publisher","first-page":"191","DOI":"10.1517\/14740330902733961","volume":"8","author":"MW Saif","year":"2009","unstructured":"Saif, M. W., Shah, M. M., & Shah, A. R. (2009). Fluoropyrimidine-associated cardiotoxicity: Revisited. Expert Opinion on Drug Safety,8(2), 191\u2013202.","journal-title":"Expert Opinion on Drug Safety"},{"issue":"3","key":"9562_CR17","doi-asserted-by":"publisher","first-page":"566","DOI":"10.1016\/0002-9343(87)90465-7","volume":"82","author":"NS Kleinman","year":"1987","unstructured":"Kleinman, N. S., Lehane, D. E., Geyer, C. E., et al. (1987). Prinzmetal\u2019s angina during 5-fluorouracil chemotherapy. American Journal of Medicine,82(3), 566\u2013568.","journal-title":"American Journal of Medicine"},{"key":"9562_CR18","doi-asserted-by":"publisher","first-page":"1507","DOI":"10.1038\/sj.bjc.6600967","volume":"88","author":"G Cianci","year":"2003","unstructured":"Cianci, G., Morelli, M. F., Cannita, K., et al. (2003). Prophylactic options in patients with 5-fluorouracil-associated cardiotoxicity. British Journal of Cancer,88, 1507\u20131509.","journal-title":"British Journal of Cancer"},{"issue":"27","key":"9562_CR19","doi-asserted-by":"publisher","first-page":"4217","DOI":"10.1200\/JCO.2006.09.2684","volume":"25","author":"R Porschen","year":"2007","unstructured":"Porschen, R., Arkenau, H. T., Kubicka, S., et al. (2007). Phase III study of capecitabine plus oxaliplatin compared with fluorouracil and leucovorin plus oxaliplatin in metastatic colorectal cancer: A final report of the AIO Colorectal Study Group. Journal of Clinical Oncology,25(27), 4217.","journal-title":"Journal of Clinical Oncology"},{"issue":"5","key":"9562_CR20","doi-asserted-by":"publisher","first-page":"797","DOI":"10.1093\/annonc\/mdf035","volume":"13","author":"N Frickhofen","year":"2002","unstructured":"Frickhofen, N., Beck, F. J., Jung, B., et al. (2002). Capecitabine can induce acute coronary syndrome similar to 5-fluorouracil. Annals of Oncology,13(5), 797\u2013801.","journal-title":"Annals of Oncology"}],"container-title":["Cardiovascular Toxicology"],"original-title":[],"language":"en","link":[{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1007\/s12012-020-09562-w.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/article\/10.1007\/s12012-020-09562-w\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1007\/s12012-020-09562-w.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2024,7,29]],"date-time":"2024-07-29T23:49:35Z","timestamp":1722296975000},"score":1,"resource":{"primary":{"URL":"http:\/\/link.springer.com\/10.1007\/s12012-020-09562-w"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2020,1,10]]},"references-count":20,"journal-issue":{"issue":"4","published-print":{"date-parts":[[2020,8]]}},"alternative-id":["9562"],"URL":"https:\/\/doi.org\/10.1007\/s12012-020-09562-w","relation":{},"ISSN":["1530-7905","1559-0259"],"issn-type":[{"value":"1530-7905","type":"print"},{"value":"1559-0259","type":"electronic"}],"subject":[],"published":{"date-parts":[[2020,1,10]]},"assertion":[{"value":"10 January 2020","order":1,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Compliance with Ethical Standards"}},{"value":"The authors declare that they have no conflict of interest.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Conflict of interest"}}]}}